Course Information

PROVIDER STATEMENT

This activity is provided by Integrity CE, LLC and Tumor Board Tuesday.

DISCLOSURE OF COMMMERCIAL SUPPORT

This activity is supported by medical education grants from Exelixis, Inc., Ipsen Biopharmaceuticals, Inc., and Taiho Oncology, Inc.

MODERATOR

Michael J. Pishvaian, MD, PhD
Associate Professor, Department of Oncology
Director of the Gastrointestinal, Development Therapeutics, and Clinical Research Programs at the NCR
Kimmel Cancer Center at Sibley Memorial Hospital
Johns Hopkins University School of Medicine
Washington, District of Columbia

SCHEDULE

#TumorBoardTuesday takes place on Tuesdays at 8:00 PM Eastern Time.

Date	Topic	Faculty	Disclosures
Tuesday, July 8, 2025	Optimizing 1L Treatment Selection in mPDAC AMA credit	Shubham Pant, MD, MBBS Professor Department of Gastrointestinal Medical Oncology The University of Texas MD Anderson Cancer Center Houston, Texas Daniel Haldar, MD Assistant Professor Department of Gastrointestinal Medical Oncology The University of Texas MD Anderson Cancer Center Houston, Texas	Shubham Pant, MD, MBBS Consulting or Advisory Role: Alligator Bioscience, Arcus, AskGene Pharma, AstraZeneca, Boehringer Ingelheim, BPGBio, BristolMyersSquibb, Ipsen, Janssen, Jazz Pharmaceuticals, Merck, Nihon Medi-Physics Co, Ltd, Novartis, Pfizer, Revolution Medicine, Theriva Biosciences, USWorldmeds, Zymeworks Research Funding to Institution: Amal Therapeutics, Arcus, Astellas, Biontech, Boehringer Ingelheim, BristolMyersSquibb, Elicio, Framewave, Immuneering, ImmunoMET, Ipsen, Janssen, Jazz Therapeutics, Lilly, Mirati Therapeutics, NGM Pharmaceuticals, Novartis, Pfizer, Revolution Medicine, Zymeworks Stock: Telperian Daniel Haldar, MD Consultant: Sift Biosciences Research Funding from Institution: BristolMyersSquibb, Shionogi, Summit Therapeutics Travel/Honoraria: DAVA Oncology
Tuesday, April 1, 2025	Management of Advanced Neuroendocrine Tumors AMA Credit	Rachel Riechelmann, MD, PhD Medical Oncologist Director - Clinical Oncology Department and Head Neuroendocrine Tumors Cancer Reference Center AC Camargo Cancer Center Sao Paulo, Brazil Guilherme Rossato, MD Medical Oncologist AC Camargo Cancer Center Sao Paulo, Brazil	Rachel Riechelmann, MD, PhD Advisory Board: Ipsen Guilherme Rossato, MD has no real or apparent conflicts to disclose.

Date

Topic

Faculty

Disclosures

Tuesday, July 8, 2025

Optimizing 1L Treatment Selection in mPDAC
AMA credit

Shubham Pant, MD, MBBS
Professor

Department of Gastrointestinal Medical Oncology

The University of Texas MD Anderson Cancer Center

Houston, Texas

Daniel Haldar, MD
Assistant Professor

Department of Gastrointestinal Medical Oncology

The University of Texas MD Anderson Cancer Center

Houston, Texas

Shubham Pant, MD, MBBS
Consulting or Advisory Role: Alligator Bioscience, Arcus, AskGene Pharma, AstraZeneca, Boehringer Ingelheim, BPGBio, BristolMyersSquibb, Ipsen, Janssen, Jazz Pharmaceuticals, Merck, Nihon Medi-Physics Co, Ltd, Novartis, Pfizer, Revolution Medicine, Theriva Biosciences, USWorldmeds, Zymeworks

Research Funding to Institution: Amal Therapeutics, Arcus, Astellas, Biontech, Boehringer Ingelheim, BristolMyersSquibb, Elicio, Framewave, Immuneering, ImmunoMET, Ipsen, Janssen, Jazz Therapeutics, Lilly, Mirati Therapeutics, NGM Pharmaceuticals, Novartis, Pfizer, Revolution Medicine, Zymeworks

Stock: Telperian

Daniel Haldar, MD
Consultant: Sift Biosciences

Research Funding from Institution: BristolMyersSquibb, Shionogi, Summit Therapeutics

Travel/Honoraria: DAVA Oncology

Tuesday, April 1, 2025

Management of Advanced Neuroendocrine Tumors

AMA Credit

Rachel Riechelmann, MD, PhD
Medical Oncologist
Director - Clinical Oncology Department and Head
Neuroendocrine Tumors Cancer Reference Center
AC Camargo Cancer Center
Sao Paulo, Brazil

Guilherme Rossato, MD
Medical Oncologist
AC Camargo Cancer Center
Sao Paulo, Brazil

Rachel Riechelmann, MD, PhD
Advisory Board: Ipsen

Guilherme Rossato, MD has no real or apparent conflicts to disclose.

Stay tuned for upcoming conversations!

PROGRAM OVERVIEW

Oncologists and other clinicians who treat patients with gastrointestinal (GI) cancers have generally adopted molecular profiling technologies offering insight into the molecular underpinning of colorectal, gastric, esophageal, and biliary tumors. Considering the challenges of managing these tumor types, understanding these molecular alterations is critical to incorporating newly approved and emerging targeted agents, including immunotherapies. Yet, translating these findings into clinical applications can be challenging. Determining which potential biomarkers and/or druggable mutations in GI cancers that benefit patients is instrumental in improving patient outcomes. Oncologists need greater understanding and insight into the foundational genomic discoveries that underly the use of targeted entities.

Tumor Board Tuesday is a regularly scheduled, Twitter-based case discussion forum led by expert faculty modeled on the traditional tumor board presentation. Cases are based on realistic scenarios and supporting data is included for optimal treatment selection and patient management.

Learning Objectives

TARGET AUDIENCE

This educational activity has been designed to meet the needs of medical, surgical, and radiation oncologists, gastroenterologists, physician assistants, nurse practitioners, nurses, and other healthcare providers involved in the treatment of gastrointestinal cancers.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants will be able to:

Integrate genomic, immunogenic, and proteomic aberration assessments to guide treatment decisions
Select personalized therapeutic regimens consistent with current evidence and best practices
Implement supportive care strategies to mitigate and manage unique toxicities associated with recently approved and emerging therapies

Faculty Information and Disclosures

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated. The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Michael L. Pishvaian, MD, PhD
Ad Hoc Advisory Boards: AstraZeneca, Ideaya, Merck, Merus, Seattle Genetics
Educational (Unbranded) Program Speaker: Novartis, Pfizer
Steering Committee: Astellas, Pionyr, Trisalus
Funding to Institution: Amgen, Arcus Bio, Biomed Valley, Boerhinger Ingelheim, Ideaya, Seattle Genetics, Merck, Novartis, Pfizer, RenovoRx, Repare Tx, Tesaro, Tizonia
Stock Ownership: Perthera, Inc.

The Integrity CE, LLC planners and managers and Tumor Board Tuesday patient planners do not have any financial relationships or relationships to products or devices with ineligible companies.

Accreditation Information

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. To receive credit, participants must:

Read the learning objectives and faculty disclosures
Complete the pretest
Study the educational activity
Complete the posttest and the evaluation form

If you wish to claim credit for your participation in TBT conversations from April 1, 2025 – March 31, 2026, you can do so here: https://www.integrityce.com/TBTeval25

ACCREDITATION STATEMENT

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this Other activity (a regularly scheduled social media-based tumor board) for a maximum of 5.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimers and Technical Requirements

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent) Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS Plug-in: Adobe^® Flash^® Player 10

Adobe^® Flash^® Player 10 plug-in should be downloaded
Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below: Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Tumor Board Tuesday 2025: Gastrointestinal Cancers